Tag : GW Pharmaceuticals

Politics

DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug

Editor
The Drug Enforcement Administration (DEA) has given the Cannabidiol (CBD) derived pharmaceutical product, Epidiolex, a reported Schedule V status. The newly approved drug is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The CBD product Epidiolex is derived from the cannabis...
Current News Market Watch Uncategorized

FDA Approves GW Pharma’s CBD Derived Epidiolex to Treat Epilepsy

Editor
The United States Food & Drugs Administration (FDA) has officially approved GW Pharmaceuticals’ (NASDAQ: GWPH) Cannabidiol (CBD) derived medication called Epidiolex. The newly approved drug is a oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The new CBD derived pharmaceutical will be...
Current News Market Watch Uncategorized

GW Pharmaceuticals CBD Based Drug Could Receive FDA Approval Soon

Editor
WASHINGTON (AP) — A medicine made from the marijuana plant moved one step closer to U.S. approval Thursday after federal health advisers endorsed it for the treatment of severe seizures in children with epilepsy. If the Food and Drug Administration follows the group’s recommendation, GW Pharmaceuticals’ syrup would become the...
Current News Market Watch Uncategorized

GW Pharmaceuticals Receives Approval for 5 New Patents for Epidiolex

Editor
GW Pharmaceuticals (Nasdaq:GWPH) recently announced that their company has received “Notices of Allowance” from the United States Patent and Trademark office for five new Epidiolex® patent applications for the company’s proprietary Cannabidiol (CBD) based pharmaceutical. Epidiolex® is concentrated on treating rare, treatement resistant epilepsy conditions such as Dravet syndrome, Lennox-Gastaut...
Cash Crop 150 CCT Voice

Top 10 Public Companies with the Largest Market Caps in Cannabis

Editor
10. Emerald Health Therapeutics Inc. (TSX: EMH) $674 Million Emerald Health Therapeutics, Inc. operates through Emerald Health Therapeutics Canada Inc. (“EHTC”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through EHTC, Emerald is authorized to produce and sell dried cannabis and cannabis oil for...
Current News Health

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

Editor
On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s...
Current News Market Watch Uncategorized

Will GW Pharmaceuticals Shape How Cannabis is Viewed in the U.S.?

kristen fisher
GW Pharmaceuticals is a Salisbury, England company who are utilizing U.S. patents to secure cannabis are a functioning medical treatment drug. Because these U.S. patents can be used to further GW Pharma seems bizarre since, (based on two federal agencies) who deny that cannabis should be considered helpful in terms...